

MP0310

FAP x 4-1BB (FAP-Mediated Tumor Accumulation) is a multi-specific DARPin® simultaneously 4-1BB and FAP and is the first of a series of tumor-restricted agonists tumor-localized binding to FAP that only activate immune cells in the tumor and not in the rest of the body thereby allowing full activation and potentially opening the therapeutic window for combinations.

Clustering of 4-1BB via FAP binding to maximize 4-1BB agonism Local 4-1BB activation has the potential to stimulate tumor-local T-cells MP0310 has the potential to synergize with a range of other IO approaches

pre-clinical data of MP0310 as well as the rationale of MP0250 in EGFR mutated NSCLC (Non-small Cell Lung Cancer). MP0310: A 4-1BB/FAP bispecific DARPin® drug candidate promoting tumor-restricted T-cell co-stimulation

Amgen has strong pipeline of IO drug candidates that have the potential to synergize with MP0310. Collaboration and license agreement for the development of MP0310 DARPin® candidate Co-funding of clinical development: – Parties will share costs in defined percentages for first 3 indications subject to certain conditions – For all additional clinical trials, Amgen is responsible for all development costs MP retains certain rights to develop and commercialize its own products in combination with MP0310.